Inspire Medical Systems INSP is well-positioned for solid growth over the next few quarters as it navigates a significant product transition.
Shares of this Zacks Rank #1 (Strong Buy) company have declined 33.1% in the year-to-date period against a 12.2% gain for both the industry and the S&P 500 Index.
Inspire Medical, a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), has a market capitalization of $1.66 billion.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 195.9%.
Image Source: Zacks Investment Research
Factors Driving INSP’s Prospects
Inspire V Adoption & Strong Clinical Evidence: Inspire Medical continues to strengthen its competitive position in OSA through the broader adoption of its Inspire V system and a growing body of clinical evidence. In the company’s Singapore clinical study, all 44 implants were completed successfully, surgical time was reduced by 20%, and therapy adherence averaged 5.9 hours per night. A limited U.S. market release involving 101 patients also showed 100% successful implantation and continued therapy use, with average adherence of 6.3 hours per night at six months.
INSP is also expanding the evidence base supporting Inspire therapy beyond sleep-related outcomes, with recent research finding lower odds of stroke, myocardial infarction, atrial fibrillation, hospitalization and acute heart failure among patients receiving hypoglossal nerve stimulation compared with CPAP. The PREDICTOR study could further simplify the treatment pathway by allowing certain patients to avoid drug-induced sleep endoscopy (DISE), potentially reducing barriers to treatment. With more than 400 publications, this growing evidence base supports physician confidence in Inspire therapy.
Large Underpenetrated Market & Expanding Patient Access: Inspire Medical has substantial room for long-term expansion, with its addressable OSA market still less than 5% penetrated. The company estimates a U.S. market opportunity of more than $10 billion, providing a broad foundation for future adoption. Management is also working to reduce patient-access bottlenecks through Project Horizon, SleepSync initiatives, expanded ENT capacity, surgeon training and new treatment centers. International markets offer additional growth potential, particularly Continental Europe, where France has seen strong momentum following nationwide reimbursement, alongside continued expansion across Germany, Austria, Switzerland, the Netherlands, Belgium, the U.K., Japan and Singapore.
Regulatory Expansion & Clinical Scale: Inspire Medical has treated more than 140,000 patients and has over 1,500 implanters, supported by reimbursement coverage for more than 300 million U.S. lives. Inspire V represented the majority of implants in the second quarter of 2026. Coding clarity is also improving, with new facility C-codes in place and CMS proposing higher 2027 Medicare facility reimbursement. The company has also resubmitted its application for a Category I CPT code, targeting implementation in January 2028, which could further strengthen the long-term reimbursement framework.
Key Challenges for INSP Stock
Coding, Reimbursement and WISeR Headwinds: Inspire Medical continues to face coding and reimbursement disruption for Inspire V, with inconsistent surgeon payments and administrative complexity under the WISeR prior authorization program across six Medicare pilot states. These issues affected second-quarter 2026 revenues by approximately $40 million and are expected to reduce full-year 2026 revenues by $120-$130 million, while the revised Category I CPT application remains pending. Although customer education and prior authorization support are improving, state-level variability and billing uncertainty could continue to slow procedure conversion and Medicare growth.
Potential GLP-1 Therapy Pressure: Growing use of GLP-1 therapies could delay some Inspire treatment decisions as physicians may prioritize weight-loss treatment before considering Inspire. This sequencing can extend the patient journey and reduce near-term procedure conversion. However, management believes GLP-1 adoption could eventually expand the addressable pool by helping patients reduce BMI while leaving OSA unresolved. The impact remains uncertain as prescribing patterns, patient behavior and payer coverage continue to evolve.
Inspire Medical Systems, Inc. Price
Inspire Medical Systems, Inc. price | Inspire Medical Systems, Inc. Quote
Estimate Trend
Inspire Medical is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 33.3% to $1.24 per share.
The Zacks Consensus Estimate for third-quarter 2026 revenues and loss per share is pegged at $204.1 million and 11 cents, respectively.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.
Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.